GlassScriptPhysician profile
Mary Beth Wiles
NPI 1407863285
$7,014.21
in general payments reported to CMS, 2019-2025
40 companies · $1,381 in 2025
The $1,381 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $796 · 2021: $885 · 2022: $1,431 · 2023: $974 · 2024: $849 · 2025: $1,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,204.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,001.87 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $990.94 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $600.20 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $399.46 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $397.26 | 2021-2025 | |
| Lilly USA, LLC | $372.55 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Radius Health, INC. | $364.82 | 2019-2025 | Tymlos |
| Abbvie INC. | $355.82 | 2020-2025 | Vraylar |
| Glaxosmithkline, LLC. | $285.06 | 2020-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $284.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $244.23 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.75 | 2019-2025 | Jardiance, Ofev |
| Sumitomo Pharma America, INC. | $177.19 | 2024-2025 | Gemtesa |
| Corcept Therapeutics | $172.91 | 2024-2025 | Korlym |
| Madrigal Pharmaceuticals | $159.45 | 2025 | Rezdiffra |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $107.13 | 2023 | Hillrom - Eli280 Cardiograph, Hillrom - Eli 280 |
| Sanofi-Aventis U.S. LLC | $97.29 | 2021-2025 | |
| Eisai INC. | $91.43 | 2021-2025 | |
| Boston Scientific Corporation | $67.12 | 2024-2025 | Bodyguardian |
| Merck Sharp & Dohme LLC | $62.54 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $60.66 | 2020-2021 | |
| Esperion Therapeutics, INC. | $43.99 | 2020-2024 | Nexletol |
| Astellas Pharma US INC | $41.20 | 2022-2023 | Veozah |
| Sanofi Pasteur INC. | $40.56 | 2025 | |
| Ferring Pharmaceuticals INC. | $38.98 | 2024-2025 | Rebyota |
| Otsuka America Pharmaceutical, INC. | $38.73 | 2019-2023 | Rexulti |
| Mylan Specialty L.P. | $35.71 | 2019 | |
| Exact Sciences Corporation | $34.41 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $26.56 | 2019-2020 | |
| Dexcom, INC. | $25.59 | 2021 | |
| Lundbeck LLC | $23.74 | 2023 | Vyepti |
| Abiomed | $23.45 | 2024 | Impella |
| Insulet Corporation | $22.34 | 2023 | Omnipod |
| Echosens North America, INC. | $20.46 | 2025 | Fibroscan |
| Athena Bioscience, LLC | $17.77 | 2024 | Qdolo |
| Xeris Pharmaceuticals, INC. | $16.85 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.36 | 2019 | |
| Daiichi Sankyo INC. | $15.32 | 2022 | |
| Currax Pharmaceuticals LLC | $12.54 | 2022 | |
| Nestle Healthcare Nutrition INC. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Beth Wiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.